Insider Sale at Spark Therapeutics (ONCE) Continues Selling Trend

Tuesday, September 26, 2017 10:15 PM ET

Insider Sale at Spark Therapeutics (ONCE) Continues Selling Trend

A filing with the SEC today disclosed a substantial insider sale of Spark Therapeutics shares as — Children’s Hospital of Philadelphia Foundation, 10% Owner and Director — sold 1,000,000 shares in the company having a market value of approximately $84,630,000. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 211,858 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 1,211,858 shares and have averaged 605,929 shares per transaction over this time period.

Insider buy/sell trading at Spark Therapeutics is above the 266 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 306 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Spark Therapeutics insiders was also higher. Within the peer group there were 9,239,272 shares purchased and 16,879,465 shares sold with company insiders selling 24,968 shares on average.

In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data sourced to evaluate and write this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.